Cost-effectiveness analysis of universal newborn screening for medium chain acyl-CoA dehydrogenase deficiency in France
Open Access
- 8 June 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Pediatrics
- Vol. 12 (1), 60
- https://doi.org/10.1186/1471-2431-12-60
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- The National Austrian Newborn Screening Program – Eight years experience with mass spectrometry. Past, present, and future goalsWiener klinische Wochenschrift, 2010
- Four years of expanded newborn screening in Portugal with tandem mass spectrometryJournal of Inherited Metabolic Disease, 2010
- Progress in expanded newborn screening for metabolic conditions by LC‐MS/MS in Tuscany: Update on methods to reduce false testsJournal of Inherited Metabolic Disease, 2008
- Neonatal screening for medium‐chain acyl‐CoA dehydrogenase (MCAD) deficiency in The Netherlands: The importance of enzyme analysis to ascertain true MCAD deficiencyJournal of Inherited Metabolic Disease, 2008
- Expanded newborn screening in Europe 2007Journal of Inherited Metabolic Disease, 2007
- Recent advances in newborn screeningJournal of Inherited Metabolic Disease, 2007
- The tandem mass spectrometry newborn screening experience in North Carolina: 1997–2005Journal of Inherited Metabolic Disease, 2006
- Expanding screening for rare metabolic disease in the newborn: An analysis of costs, effect and ethical consequences for decision‐making in FinlandActa Paediatrica, 2005
- Newborn screening for medium chain acyl-CoA dehydrogenase deficiency: evaluating the effects on outcomeEuropean Journal of Pediatrics, 2003
- Medium–chain acyl-coenzyme A dehydrogenase deficiency: Clinical course in 120 affected childrenThe Journal of Pediatrics, 1994